Skip to main content
. Author manuscript; available in PMC: 2009 Jan 29.
Published in final edited form as: Mol Ther. 2008 May 20;16(7):1252–1260. doi: 10.1038/mt.2008.100

Figure 6. The transduction efficiency of chimeric-1829 and its mutants.

Figure 6

(a) Diagram of the chimeric capsid constructs and site point mutants. (b) Fluorescence micrographs of green fluorescent protein transgene expression in CS1 cells transduced with AAV1829 and its mutants at a multiplicity of infection (MOI) of 1,000 for 48 hours. (c) Luciferase transgene expression in CS1 cells transduced with AAV1829 and its mutants at an MOI of 1,000 for 48 hours. 1, Chimeric-1829; 2, AAV182; 3, AAV2–9; 4, chimeric-1829 Y706N; 5, Chimeric-1829 A714T; 6, Chimeric-1829 N716D; 7, Chimeric-1829 E718N; 8, AAV2; 9, AAV129. AAV, adeno-associated virus; RLU, relative luciferase unit.